Zobrazeno 1 - 10
of 721
pro vyhledávání: '"Chadi, Nabhan"'
Autor:
PR Newswire
Publikováno v:
PR Newswire US. 05/22/2024.
Autor:
Margaret Meagher, Harris Krause, Andrew Elliott, Alex Farrell, Emmanuel S. Antonarakis, Bruno Bastos, Elisabeth I. Heath, Christina Jamieson, Tyler F. Stewart, Aditya Bagrodia, Chadi Nabhan, Matt Oberley, Rana R. McKay, Amirali Salmasi
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Background Non‐canonical WNT family (WNT5A pathway) signaling via WNT5A through ROR1 and its partner, ROR2, or Frizzled2 (FZD2) is linked to processes driving tumorigenesis and therapy resistance. We utilized a large dataset of urothelial
Externí odkaz:
https://doaj.org/article/a30f09f80e6e49edbc6a718dbeadeb97
Autor:
Jeff P. Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, Mecide M. Gharibo, E. Dawn Flick, Andrew Trigg, Anthony Mato
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 188-198 (2020)
Abstract Health‐related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT
Externí odkaz:
https://doaj.org/article/34c06b8e749f4507ab23a49de144c417
Publikováno v:
Translational Oncology, Vol 14, Iss 8, Pp 101093- (2021)
Externí odkaz:
https://doaj.org/article/b0dd846f039647d3b8bf5d1874d731f6
Autor:
Justin Hwang, Xiaolei Shi, Andrew Elliott, Taylor E. Arnoff, Julie McGrath, Joanne Xiu, Phillip Walker, Hannah E. Bergom, Abderrahman Day, Shihab Ahmed, Sydney Tape, Allison Makovec, Atef Ali, Rami M. Shaker, Eamon Toye, Rachel Passow, John R. Lozada, Jinhua Wang, Emil Lou, Kent W. Mouw, Benedito A. Carneiro, Elisabeth I. Heath, Rana R. McKay, W. Michael Korn, Chadi Nabhan, Charles J. Ryan, Emmanuel S. Antonarakis
Publikováno v:
Clinical Cancer Research. :OF1-OF12
Purpose: In patients with metastatic prostate cancer (mPC), ATM and BRCA2 mutations dictate differences in PARPi inhibitor response and other therapies. We interrogated the molecular features of ATM- and BRCA2-mutated mPC to explain the divergent cli
Autor:
Jim Abraham, Amy B. Heimberger, John Marshall, Elisabeth Heath, Joseph Drabick, Anthony Helmstetter, Joanne Xiu, Daniel Magee, Phillip Stafford, Chadi Nabhan, Sourabh Antani, Curtis Johnston, Matthew Oberley, Wolfgang Michael Korn, David Spetzler
Publikováno v:
Translational Oncology, Vol 14, Iss 3, Pp 101016- (2021)
Cancer of Unknown Primary (CUP) occurs in 3–5% of patients when standard histological diagnostic tests are unable to determine the origin of metastatic cancer. Typically, a CUP diagnosis is treated empirically and has very poor outcomes, with media
Externí odkaz:
https://doaj.org/article/469bb8ab092d4f4b969ca0049de6630e
Autor:
Charles L. Bennett, Shamia Hoque, Nancy Olivieri, Matthew A. Taylor, David Aboulafia, Courtney Lubaczewski, Andrew C. Bennett, Jay Vemula, Benjamin Schooley, Bartlett J. Witherspoon, Ashley C Godwin, Paul S. Ray, Paul R. Yarnold, Henry C. Ausdenmoore, Marc Fishman, Georgne Herring, Anne Ventrone, Juan Aldaco, William J. Hrushesky, John Restaino, Henrik S. Thomsen, Robert Marx, Cesar Migliorati, Salvatore Ruggiero, Chadi Nabhan, Kenneth R. Carson, June M. McKoy, Y. Tony Yang, Martin W. Schoen, Kevin Knopf, Linda Martin, Oliver Sartor, Steven Rosen, William K. Smith
Publikováno v:
EClinicalMedicine, Vol 31, Iss , Pp 100693- (2021)
Background: Adverse drug/device reactions (ADRs) can result in severe patient harm. We define very serious ADRs as being associated with severe toxicity, as measured on the Common Toxicity Criteria Adverse Events (CTCAE)) scale, following use of drug
Externí odkaz:
https://doaj.org/article/7660e72814e34fe8aaa2b0680f081e61
Autor:
Andrew Elliott, Francesca Battaglin, Heinz-Josef Lenz, Kai Zimmer, Chadi Nabhan, Clemens Feistritzer
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Introduction Poly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of BRCA-mutated (mut) breast cancers and are under extensive evaluation for BRCA- and PALB2-mutated pancreatic ductal adenocarcinoma (PDAC). However, the
Externí odkaz:
https://doaj.org/article/0347abaead1044929c2995d0b75ebc83
Autor:
Toby A. Eyre, Nicole Lamanna, Lindsey E. Roeker, Chaitra S. Ujjani, Brian T. Hill, Paul M. Barr, Erick Lansigan, Bruce D. Cheson, Maryam Yazdy, John N. Allan, Joanna Rhodes, Stephen J. Schuster, Chadi Nabhan, Alan Skarbnik, Lori Leslie, Prioty Islam, Katherine Whitaker, Catherine C. Coombs, Hande H. Tuncer, John M. Pagel, Ryan Jacobs, Allison M. Winter, Neil Bailey, Andrea Sitlinger, Anna H. Schuh, George Follows, Christopher P. Fox, Danielle M. Brander, Mazyar Shadman, Anthony R. Mato
Publikováno v:
Haematologica, Vol 106, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/ad08843e37b24e96ad4960bf18e8f92a
Autor:
Shamia Hoque, Brian J Chen, Martin W Schoen, Kenneth R Carson, Jesse Keller, Bartlett J Witherspoon, Kevin B Knopf, Y Tony Yang, Benjamin Schooley, Chadi Nabhan, Oliver Sartor, Paul R Yarnold, Paul Ray, Laura Bobolts, William J Hrushesky, Michael Dickson, Charles L Bennett
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234541 (2020)
Erythropoisis stimulating agent (ESA) use was addressed in Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) meetings between 2004 and 2008. FDA safety-focused regulatory actions occurred in 2007 and 2008. In 2007, black box
Externí odkaz:
https://doaj.org/article/db22cc567bfb42b08476116e945c2620